Valeant Pharmaceuticals Announces New Management Appointment

MONTREAL, Jan. 3, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced today that Laizer D. Kornwasser has been 
named to Valeant's Executive Management Team and will assume the role of 
Executive Vice President/Company Group Chairman where he will be responsible 
for our operations in Canada, U.S. Neurology and various other U.S. functions 
including managed care and distribution, effective February 1, 2013. 
Laizer D. Kornwasser was a Senior Executive at Medco Health prior to its 
acquisition by Express Scripts. At Medco he reported directly into the CEO and 
was a member of Executive Committee. He served as Senior Vice President, 
Consumer Solutions and Retail Markets and was responsible for retail network 
and mail pharmacy products and strategy. He oversaw network pricing, 
negotiations, plan designs and programs that maximized the retail and mail 
channels. Mr. Kornwasser was also responsible for the integrated care solution 
for Medco's six million members with diabetes. Mr. Kornwasser joined Medco in 
August 2003, and was initially responsible for building a business development 
team, post spin-off from Merck. In this role he oversaw all acquisitions, 
joint ventures and was actively involved in developing the company's long-term 
growth strategy. He later assumed responsibility for the companies' channel 
and generic drug strategy and was President of its diabetes division, which 
focused on direct to consumer solutions. Prior to joining Medco, Mr. 
Kornwasser held positions at Merrill Lynch and Coopers & Lybrand, and served 
as an associate professor at Yeshiva University. He has an MBA from Harvard 
Business School and a BS in Accounting from Yeshiva University. 
"The Board of Directors and I are pleased to add Laizer as the final 
complement to our senior management team," said J. Michael Pearson, chairman 
and chief executive officer.  "Laizer's broad health care experience that 
ranges from running large divisions, overseeing acquisitions and strategy, to 
understanding the retail and mail channels, will be invaluable to us. And with 
our management team now complete, I believe Valeant is well positioned to 
capitalize on the opportunities that lie ahead." 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of neurology, 
dermatology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Forward-Looking Statements 
This press release may contain forward-looking statements. These 
forward-looking statements relate to, among other things, the opportunities 
that lie ahead and the future roles of certain management. Forward-looking 
statements can generally be identified by the use of words such as "believe," 
"anticipate," "expect," "estimate," "intend," "continue," "plan," "project," 
"will," "may," "should," "could," "would," "target," "potential," and other 
similar expressions.  In addition, any statements that refer to expectations, 
projections or other characterizations of future events or circumstances are 
forward-looking statements.  Actual results may differ materially from those 
expressed or implied in such statements.  Important factors that could cause 
actual results to differ materially from these expectations include, among 
other things, the ability of Valeant to capitalize on opportunities, the 
changing roles of management and the risk factors as detailed from time to 
time in Valeant's reports filed with the Securities and Exchange Commission 
and the Canadian Securities Administrators.   Readers are cautioned not to 
place undue reliance on any of these forward-looking statements. Valeant 
undertakes no obligation to update any of these forward-looking statements to 
reflect events or circumstances after the date of this press release. 
Contact Information:  Laurie W. Little  949-461-6002  laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2013/03/c3860.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: HEA MTC 2575 WNEWS  
-0- Jan/03/2013 13:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.